Silk Road Medical Announces Key TCAR Presentations at the Society for Vascular Surgery 2019 Vascular Annual Meeting

Via: Vascular Disease Management

SUNNYVALE, Calif. – June 4, 2019 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

Data from the Society for Vascular Surgery’s TCAR Surveillance Project, launched in 2016 to obtain real-world comparative outcomes of TCAR and other carotid artery treatments from centers participating in the Vascular Quality Initiative (VQI), will be featured in podium and poster presentations, including:

• “Age and Outcomes After TransCarotid Artery Revascularization (TCAR), Transfemoral Carotid Artery Stenting (TF-CAS) and Carotid Endarterectomy (CEA)” (VESS14) will be presented by Dr. Hanaa Dakour Aridi of Johns Hopkins University School of Medicine during VESS Paper Session 1 on Wednesday, June 12 at 10:45 a.m. ET in Maryland D.
• “Outcomes of TransCarotid Artery Revascularization (TCAR) versus Carotid Endarterectomy (CEA) in the TCAR Surveillance Project” (SSO1) will be presented by Dr. Mahmoud Malas of the University of California, San Diego School of Medicine on Thursday, June 13 at 8:30 a.m. ET in Potomac A/B.

Read More: https://www.vasculardiseasemanagement.com/content/silk-road-medical-announces-key-tcar-presentations-society-vascular-surgery-2019-vascular